EGFR and lung cancer: Its low toxicities [38,39], associated with its potential to inhibit several proteins associated with lung cancer (tyrosine kinase, telomerase, NF-κB, ERK1/2, EGFR, STAT proteins, HSP 90, PI3K, Bax, among others) [24,26,28], makes them promising prototypes for the development of new anti-lung cancer drugs.